Molindone for schizophrenia and severe mental illness

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2007, Pages

  Bagnall, Anne Marie ^a   Fenton, M ^b   Kleijnen, J ^b   Lewis, R ^b  

^a LEEDS METROPOLITAN UNIVERSITY   (United Kingdom)

^b NONE

Author keywords

Antipsychotic agents *therapeutic use ; Humans; Mental disorders drug therapy ; Molindone *therapeutic use ; Randomized controlled trials as topic; Schizophrenia *drug therapy

Indexed keywords

CHLORPROMAZINE; HALOPERIDOL; MOLINDONE; PLACEBO; THIORIDAZINE; TRIFLUOPERAZINE;

ABNORMAL LABORATORY RESULT; AKATHISIA; AKINESIA; ANOREXIA; APPETITE; ARTHRALGIA; AUTONOMIC DYSFUNCTION; BEHAVIOR DISORDER; BLURRED VISION; CATARACT; CINAHL; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; CONFUSION; CONSTIPATION; DISEASE SEVERITY; DROWSINESS; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPHAGIA; EMBASE; FOLLOW UP; HEADACHE; HICCUP; HUMAN; HYPERKINESIA; HYPERSALIVATION; HYPOKINESIA; HYPOTENSION; LACTATION; MEDICAL LITERATURE; MEDLINE; MENTAL DISEASE; MOTOR ACTIVITY; MOTOR DYSFUNCTION; MUSCLE CRAMP; MYALGIA; NAUSEA; NOSE CONGESTION; PSYCHOSIS; PSYCINFO; PUBLICATION; QRS COMPLEX; REVIEW; RIGIDITY; SCHIZOPHRENIA; SIDE EFFECT; T WAVE; TACHYCARDIA; TARDIVE DYSKINESIA; TREMOR; VOMITING; WEAKNESS; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 44949124630     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002083.pub2     Document Type: Review

References (77)

1. Binder 1981 {published data only} *Binder R, Glick I, Rice M. A comparative study of parenteral molindone and haloperidol in the acutely psychotic patient. Journal of Clinical Psychiatry 1981;42(5):203-6.
2. Brauzer 1971 {published data only} *Brauzer B, Goldstein BJ. A clinical comparison of molindone hydrochloride with trifluoperazine in psychotic outpatients. Current Therapeutic Research 1971;13(3):152-7.
3. Clark 1970 {published data only} *Clark ML, Huber WK, Sakata K, Fowles DC, Serafetinides EA. Molindone in chronic schizophrenia. Clinical Pharmacology and Therapeutics 1970;11(5):680-8.
4. Serafetinides EA. Voltage laterality in the EEG of psychiatric patients. Disease of the Nervous System 1973;34(3):190-1.
5. Serafetinides EA, Willis D, Clark ML. The EEG effects of chemically and clinically dissimilar antipsychotics: molindone versus chlorpromazine. International Pharmacopsychiatry 1971;6(2):77-82.
6. Dufresne 1993 {published data only} *Dufresne RL, Valentino D, Kass DJ. Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacology Bulletin 1993;29(2):249-55.
7. Escobar 1985 {published data only} *Escobar JI, Mann J, Keller J, Wilkins J, Mason B, Mills MJ. Comparison of injectable molindone and haloperidol followed by oral dosage forms in acutely ill schizophrenics. Journal of Clinical Psychiatry 1985;46(8):15-9.
8. Freeman 1969 {published data only} *Freeman H, Frederick AND. Comparison of trifluoperazine and molindone in chronic schizophrenic patients. Current Therapeutic Research 1969;11(11): 670-6.
9. Gallant 1968 {published data only} *Gallant DM, Bishop MP. Molindone: a controlled evaluation in chronic schizophrenic patients. Current Therapeutic Research 1968;10(9):441-7.
10. Gallant DM, Bishop MP. Molindone versus trifluoperazine. Early Clinical Drug Evaluation Units 1968:33-4.
11. Glazer 1990 {published data only} Glazer WM, Hafez H. A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophrenia Research 1990;3(5-6):315-20. [MEDLINE: 91129137].
12. Heikkinen 1993 {published data only} *Heikkinen H, Outakoski J, Merilainen V, Tuomi A, Huttunen MO. Molindone and weight loss. Journal of Clinical Psychiatry 1993;54(4):160-1.
13. Itil 1972 {published data only} *Itil TM, Polvan N, Ucok A, Eper E, Guven F, Hsu W. Comparison of the clinical and electroencelographical effects of molindone and trifluoperazine in acute schizophrenic patients. Behavioural Neuropsychiatry 1972;3(9-10): 6-13.
14. Mielke 1977 {published data only} *Mielke DH, Gallant DM. Molindone: a controlled evaluation of the intramuscular antipsychotic preparation. Current Therapeutic Research 1977;22(3):356-60.
15. Ramsay 1970 {published data only} Lehmann, Ban. Molindone versus Trifluoperazine. Psychopharmacology Bulletin 1969;6(1):103- 5.
16. *Ramsay RA, Ban TA, Lehmann HE, Saxena BM, Bennett J. A comparative study of molindone and trifluoperazine. Current Therapeutic Research 1970;12(7):438-40.
17. Simpson 1971 {published data only} *Simpson GM, Amin M, Edwards JG. A double-blind comparison of molindone and trifluoperazine in the treatment of acute schizophrenia. Journal of Clinical Pharmacology 1971:227-36.
18. Smythies 1982 {published data only} *Smythies JR, Hain J, Crews E, Grayson G. A clinical trial of injectable molindone (Moban). Current Therapeutic Research 1982;32(5):752-6.
19. Anonymous 1974 Anonymous. Molindone - a new antipsychotic drug. Medical Letter on Drugs and Therapeutics 1975;17(14):59.
20. Ayd 1974 Ayd FJ. A critical evaluation of molindone (Moban): a new indole derivative neuroleptic. Diseases of the nervous system 1974;35(10):447-52.
21. Borison 1987 *Borison RL, Shah C, White TH, Diamond BI. Atypical and typical neuroleptics and tardive dyskinesia. Psychopharmacology Bulletin 1987;23(1):218-20.
22. Claghorn 1970 *Claghorn J. Differential drug effects on social and symptomatic behaviours. Current Therapeutic Research 1970;12(9):580-4.
23. Claghorn 1985 *Claghorn JL. Review of clinical and laboratory experiences with molindone hydrochloride. Journal of Clinical Psychiatry 1985;46(8):30-3.
24. Clardy 1991 Clardy J, Daniel D G, Breslin N, Gold J, Kleinman J, Winberger D R. A trial of L-dopa and molindone in schizophrenia. Schizophrenia Research 1991;4(3):315. [MEDLINE: 74083340].
25. Davis 1976 *Davis JM. Recent developments in the drug treatment of schizophrenia. American Journal of Psychiatry 1976;133(2):208-14.
26. DeLisi 1981 *DeLisi LE, Phelps BH, Wise CD, Apostoles PS, Bigelow L, Wyatt RJ. An effect of neuroleptic medication on plasma dopamine-beta-hydroxylase activity. Biological Psychiatry 1981;16(9):873-8.
27. Gallant 1973 Gallant DM, Bishop MP, Steele CA, Bishop G, Guerrero-Figueroa R. Molindone: a crossover evaluation of capsule and tablet formulations in severely ill schizophrenic patients. Current Therapeutic Research 1973;15(12):915-8.
28. Glazer 1985 *Glazer WM, Hafez HM, Benarroche CL. Molindone and haloperidol in tardive dyskinesia. Journal of Clinical Psychiatry 1985;46(8):4-7.
29. Kellner 1976 *Kellner R, Rada RT, Egelman A, Macaluso B. Long-term study of molindone hydrochloride in chronic schizophrenics. Current Therapeutic Research 1976;20(5):686-94.
30. Mahmoud 2004 Mahmoud RA, Engelhart LM, Janagap CC, Oster G, Ollendorf D. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder: Symptoms, quality of life and resource use under customary clinical care. Clinical Drug Investigation 2004;24(5): 275-86.
31. Owen 1989 *Owen RR, Cole JO. Molindone hydrochloride: a review of laboratory and clinical findings. Journal of Clinical Psychopharmacology 1989;9(4):268-76.
32. Parent 1986 *Parent MM, Roy S, Sramek J, Lawson W, Herrera J. Effect of molindone on weight change in hospitalised schizophrenic patients. Drug Intelligence and Clinical Pharmacy 1986;20:873-5.
33. Rubin 1967a *Rubin A, Al E. EN-1733A, a new antipsychotic agent. Federation Proceedings. 1967; Vol. 26:2738.
34. Rubin 1967b *Rubin AA, Yen HC, Pfeffer M. Psychopharmacological profile of molindone. Nature 1967;216:578-9.
35. Shelton 1968 *Shelton J, Prusmack JJ, Hollister LE. Molindone a new type of antipsychotic drug. Journal of Clinical Pharmacology 1968;8(3):190-5.
36. Sikich 2001 Sikich L, Horrigan JP, Lieberman JA, Barnhill LJ, Sheitman BB, Courvoisie HE. Comparative use of olanzapine and risperidone in psychotic youth. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, USA 2001. [MEDLINE: 74083340].
37. Simpson 1968 *Simpson GM, Krakov L. A preliminary study of molindone (EN-1733A) in chronic schizophrenia. Current Therapeutic Research 1968;10(1):41-6.
38. Sugerman 1966 *Sugerman AA, Hermann J. Molindone: an indole derivative with antipsychotic activity. Clinical Pharmacology and Therapy 1966;8(2):261-5.
39. Turek 1970 *Turek IS, Ota KY, De Laocha M, Agallionos D, Kurland AA. The use of molindone in the treatment of acute psychotic states: comparison of two dosage schedules. Journal of Clinical Pharmacology 1970;10:349-55.
40. Fuentenebro 1989 *Fuentenebro F, Escobar JI, Keller J, Lopez de Ochoa EF, Vazquez C. Prediction of the therapeutic response to neuroleptics in schizophrenia [Prediccion de la respuesta al tratamiento neuroleptico en la esquizofrenia]. Psiquis: Revista de Psiquiatria, Psicologia y Psicosomatica 1989;10(1):22-8.
41. Adams 2000 Adams CE, Gray R, Daniels J, Thornley B, Philpott H, Wahlbeck K. A survey of UK consultant psychiatrists' first and second choice drug treatments for schizophrenia. Schizophrenia Research 2000;41 (1):233.
42. Altman 1996 Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
43. APA 1997 American Psychiatric Association. American Psychiatric Association Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry 1997;154(4):1-63.
44. Bagnall 2003 Bagnall AM, Jones L, Ginnelly L, Lewis R, Glanville J, Gilbody S, Davies L, Torgerson D, Kleijnen J. A systematic review of atypical antipsychotics in schizophrenia. Health Technology Assessment 2003;7(13).
45. Begg 1996 Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF. Improving the quality of randomized controlled trials. The CONSORT statement. JAMA 1996;276:637-9.
46. Bland 1997 Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
47. Boissel 1999 Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
48. Buckley 1997 Buckley PF. New dimensions in the pharmacologic treatment of schizophrenia and related psychoses. Journal of Clinical Pharmacology 1997;37:363-78.
49. Carpenter 1994 Carpenter WT Jr, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681-90.
50. Casey 1997 Casey DE. The relationship of pharmacology to side effects. Journal of Clinical Psychiatry 1997;58(10):55-62.
51. Chalmers 1983 Chalmers TC, Celano P, Sacks HS, Smith H Jr. Bias in treatment assignment in controlled clinical trials. New England Journal of Medicine 1983;309:1358-61.
52. CWG 1998 Collaborative Working Group on Clinical Trial Evaluations. Adverse effects of the atypical antipsychotics. Journal of Clinical Psychiatry 1998;59:17-22.
53. Deeks 2000 Deeks J. Issues in the selection for meta-analyses of binary data. Abstracts of 8th International Cochrane Colloquium. 2000 Oct 25-28th; Cape Town, South Africa.
54. Divine 1992 Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
55. Donner 2002 Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
56. Glazer 1997 Glazer WM, Johnstone BM. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. Journal of Clinical Psychiatry 1997;58(10):50-4.
57. Gulliford 1999 Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey. American Journal of Epidemiology 1999;149:876-83.
58. Guy 1976 Guy W. Early clinical drug evaluation (ECDEU) assessment manual for psychopharmacology. Washington, DC: National Institute of Mental Health, 1976:217-22.
59. Hamilton 1960 Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960;23:56-61.
60. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003 2003;327:557- 60.
61. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochran Library. Issue 3, 2005. Chichester, UK:: John Wiley & Sons, Ltd, 2005.
62. Honigfeld 1965 Honigfeld G, Klett CJ. The nurses' observation scale for inpatient evaluation. A new scale for measuring improvement in chronic schizophrenia. Journal of Clinical Psychology 1965;21:65-71.
63. Jadad 1996 Jadad A, Moore A, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
64. Kane 1996 Kane JM. Factors which can make patients difficult to treat. British Journal of Psychiatry 1996;169(31):10-4.
65. Kerwin 1994 Kerwin RW. The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research. British Journal of Psychiatry 1994;164:141-8.
66. Kunz 1998 Lunz R, Oxman AD. The unpredictability paradox: re-view of empirical comparisons of randomised and non-randomised controlled trials. BMJ 1998;317:1185-90.
67. Marshall 2000 Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
68. Melkersson 2004 Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004;64(7):701-23.
69. Moher 1998 Moher D, Pham Ba', Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analysis?. Lancet 1998;352:609-13.
70. Overall 1962 Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812.
71. Pickar 1995 Pickar D. Prospects for pharmacotherapy of schizophrenia. BMJ 1995;345:557-62.
72. Prosser 1989 Prosser ES, Pruthi R, Csernansky JG. Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride. Psychopharmacology 1989;99:109-16.
73. RCP 2000 Royal College of Psychiatrists. Guidelines for the care of those with schizophrenia. London: Royal College of Psychiatrists, 2000. In press.
74. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
75. Silverstone 1995 Silverstone T, Turner P. Drug treatment in psychiatry. 5th Edition. Cornwall: TJ Press, 1995.
76. Ukoumunne 19999 Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii-92.
77. Wood MacKenzie 1998 Wood MacKenzie. Review of the Global Schizophrenia Market. PharmaForum 1998;39:9.